JP7824030B2 - インフラマソームに関連する疾患又は病態を治療するための組成物及び方法 - Google Patents

インフラマソームに関連する疾患又は病態を治療するための組成物及び方法

Info

Publication number
JP7824030B2
JP7824030B2 JP2020573110A JP2020573110A JP7824030B2 JP 7824030 B2 JP7824030 B2 JP 7824030B2 JP 2020573110 A JP2020573110 A JP 2020573110A JP 2020573110 A JP2020573110 A JP 2020573110A JP 7824030 B2 JP7824030 B2 JP 7824030B2
Authority
JP
Japan
Prior art keywords
antibody
amino acid
monoclonal antibody
acid sequence
inflammation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020573110A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021528092A5 (https=
JP2021528092A (ja
Inventor
ダブリュー． キーン，ロバート
ディートリヒ，ダブリュー．ダルトン
リベロ ヴァッカリ，ジュアン パブロ デ
エム． ブラムレット，ヘレン
ブランビラ，ロベルタ
Original Assignee
ユニバーシティ オブ マイアミ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US16/026,482 external-priority patent/US10703811B2/en
Application filed by ユニバーシティ オブ マイアミ filed Critical ユニバーシティ オブ マイアミ
Publication of JP2021528092A publication Critical patent/JP2021528092A/ja
Publication of JP2021528092A5 publication Critical patent/JP2021528092A5/ja
Priority to JP2025006393A priority Critical patent/JP7850296B2/ja
Application granted granted Critical
Publication of JP7824030B2 publication Critical patent/JP7824030B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/727—Heparin; Heparan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Transplantation (AREA)
  • Pulmonology (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
JP2020573110A 2018-07-03 2019-07-03 インフラマソームに関連する疾患又は病態を治療するための組成物及び方法 Active JP7824030B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025006393A JP7850296B2 (ja) 2018-07-03 2025-01-16 インフラマソームに関連する疾患又は病態を治療するための組成物及び方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US16/026,482 US10703811B2 (en) 2016-12-29 2018-07-03 Methods and compositions for treating multiple sclerosis
US16/026,482 2018-07-03
PCT/US2019/040635 WO2020010273A1 (en) 2018-07-03 2019-07-03 Compositions and methods for treating inflammasome related diseases or conditions

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025006393A Division JP7850296B2 (ja) 2018-07-03 2025-01-16 インフラマソームに関連する疾患又は病態を治療するための組成物及び方法

Publications (3)

Publication Number Publication Date
JP2021528092A JP2021528092A (ja) 2021-10-21
JP2021528092A5 JP2021528092A5 (https=) 2022-07-08
JP7824030B2 true JP7824030B2 (ja) 2026-03-04

Family

ID=78823964

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020573110A Active JP7824030B2 (ja) 2018-07-03 2019-07-03 インフラマソームに関連する疾患又は病態を治療するための組成物及び方法
JP2025006393A Active JP7850296B2 (ja) 2018-07-03 2025-01-16 インフラマソームに関連する疾患又は病態を治療するための組成物及び方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025006393A Active JP7850296B2 (ja) 2018-07-03 2025-01-16 インフラマソームに関連する疾患又は病態を治療するための組成物及び方法

Country Status (16)

Country Link
US (1) US12570735B2 (https=)
EP (1) EP3818081A4 (https=)
JP (2) JP7824030B2 (https=)
KR (1) KR20210071944A (https=)
CN (1) CN113316588B (https=)
AU (1) AU2019297515A1 (https=)
BR (1) BR112020026798A2 (https=)
CA (1) CA3105129A1 (https=)
CL (1) CL2020003447A1 (https=)
CO (1) CO2021001172A2 (https=)
IL (1) IL279851A (https=)
MX (1) MX2021000142A (https=)
PH (1) PH12020552286A1 (https=)
SG (1) SG11202013176VA (https=)
WO (1) WO2020010273A1 (https=)
ZA (2) ZA202100703B (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20240060995A1 (en) * 2012-02-06 2024-02-22 University Of Miami Innate immune proteins as biomarkers for traumatic brain injury in adult and pediatric patients
WO2021222263A2 (en) * 2020-04-27 2021-11-04 University Of Miami Compositions and methods for treating inflammasome related diseases or conditions
US11840565B2 (en) 2016-12-29 2023-12-12 University Of Miami Methods and compositions for treating virus-associated inflammation
RU2019123160A (ru) 2016-12-29 2021-01-29 Юниверсити Оф Майами Способ модуляции активности инфламмасом и воспаления в легком
SG11202013176VA (en) 2018-07-03 2021-01-28 Univ Miami Compositions and methods for treating inflammasome related diseases or conditions
AU2022390134A1 (en) * 2021-11-16 2024-05-16 Ac Immune Sa Novel molecules for therapy and diagnosis
EP4583974A1 (en) * 2022-09-09 2025-07-16 University of Miami Inflammasome antibody compositon and method for treating neurologic disorder
WO2024114906A1 (en) * 2022-11-30 2024-06-06 Mabylon Ag Antibodies against apoptosis-associated speck-like protein containing a card (asc) and uses thereof
WO2026042012A1 (en) * 2024-08-19 2026-02-26 Institute Of Molecular And Clinical Ophthalmology Basel (Iob) Single domain antibodies and polypeptides containing same

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015016178A1 (ja) 2013-07-29 2015-02-05 国立大学法人鹿児島大学 １，５－ｄ－アンヒドロフルクトースを含むアポトーシス関連スペック様カード蛋白質の機能阻害薬
US20170107277A1 (en) 2007-07-30 2017-04-20 University Of Miami Methods of modulating inflammasome activity to treat inflammatory conditions

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2763849B1 (fr) 1997-05-28 2000-09-15 Rhone Poulenc Rorer Sa Utilisation des heparines de bas poids moleculaire pour la prevention et le traitement des oedemes cerebraux
US20040018194A1 (en) 2000-11-28 2004-01-29 Francisco Joseph A. Recombinant anti-CD30 antibodies and uses thereof
US7244764B2 (en) 2003-06-23 2007-07-17 Neurochem (International) Limited Methods and compositions for treating amyloid-related diseases
US7611707B2 (en) 2004-04-29 2009-11-03 Otsuka Pharmaceutical Co., Ltd. Glycoprotein VI antibodies and methods thereof
WO2005111283A1 (ja) * 2004-05-17 2005-11-24 Denki Kagaku Kogyo Kabushiki Kaisha ポリ塩化ビニル繊維及びその製造方法並びに人工毛髪
US7811563B2 (en) 2004-10-25 2010-10-12 Northwestern University Anti-addl antibodies and uses thereof
TW200636064A (en) 2004-10-28 2006-10-16 Centocor Inc Anti-respiratory syncytial virus antibodies, antigens and uses thereof
CA2623565A1 (en) 2005-09-28 2007-04-05 Biovascular, Inc. Methods and compositions for blocking platelet and cell adhesion, cell migration and inflammation
HUE034269T2 (en) 2005-12-29 2018-02-28 Janssen Biotech Inc Human anti-IL-23 antibodies, preparations, methods and applications
EP2447285A3 (en) 2006-05-25 2013-01-16 Momenta Pharmaceuticals, Inc. Low molecular weight heparin composition and uses thereof
KR20100014588A (ko) * 2007-02-27 2010-02-10 제넨테크, 인크. 길항제 ｏｘ40 항체 및 염증성 및 자가면역 질환의 치료에서의 이의 용도
WO2010003092A1 (en) * 2008-07-03 2010-01-07 University Of Massachusetts Methods and compositions for reducing inflammation and treating inflammatory disorders
EP2145624A1 (en) 2008-07-18 2010-01-20 Sanofi-Aventis Use of idrabiotaparinux for decreasing the incidence of bleedings during an antithrombotic treatment
EP2475380A1 (en) 2009-09-11 2012-07-18 Protaffin Biotechnologie AG Composition for treatment of cxcl8-mediated lung inflammation
US8759302B2 (en) 2010-03-16 2014-06-24 Teva Pharmaceutical Industries, Ltd. Methods of treating a subject afflicted with an autoimmune disease using predictive biomarkers of clinical response to glatiramer acetate therapy in multiple sclerosis
SMT202000095T1 (it) 2010-05-14 2020-03-13 Amgen Inc Formulazioni di anticorpi anti-sclerostina ad alta concentrazione
IT1406201B1 (it) 2010-12-10 2014-02-14 Univ Degli Studi Trieste Biomarcatori per la diagnosi della sclerosi multipla
EP2684051B1 (en) 2011-03-11 2016-04-27 Roche Diagniostics GmbH Asc as marker for chronic obstructive pulmonary disease (copd)
WO2013049278A1 (en) 2011-09-30 2013-04-04 Novartis Ag USE OF IL-1 ß BINDING ANTIBODIES
EP2812697B1 (en) 2012-02-06 2017-03-22 University of Miami Innate immune proteins as biomarkers for cns injury
TWI480044B (zh) 2012-03-16 2015-04-11 Taichung Veterans General Hospital A high molecular weight heparin or low molecular weight heparin for the preparation of a composition for at least two consecutive days of administration to improve the allergic constitution
US20140314746A1 (en) * 2013-03-13 2014-10-23 Philadelphia Health And Education Corporation, d/b/a Drexel University College of Medicine Methods for treating or preventing fibrosis in subjects afflicted with scleroderma
HK1219512A1 (zh) 2013-05-17 2017-04-07 F. Hoffmann-La Roche Ag 用於诊断和治疗炎性肠病的方法
AU2015204558B2 (en) 2014-01-10 2020-04-30 Avalyn Pharma Inc. Aerosol pirfenidone and pyridone analog compounds and uses thereof
EP3183582B1 (en) 2014-08-18 2020-02-12 The United States of America, as represented by The Secretary, Department of Health and Human Services Biomarkers for diagnosis and management of neuro-immunological diseases
CN114699409A (zh) 2014-10-16 2022-07-05 诺华股份有限公司 包含辛波莫德和拉喹莫德的用于治疗多发性硬化症的组合
US20160263183A1 (en) 2015-03-10 2016-09-15 Brown University Methods for treating lung disease
AU2016260190A1 (en) 2015-05-12 2017-11-23 The Regents Of The University Of California Peptide treatment for inflammation and fibrosis
US10195170B2 (en) 2015-08-17 2019-02-05 Twi Biotechnology, Inc. Methods for inhibiting expression of ASC, expression of NLRP3, and/or formation of NLRP3 inflammasome complex using diacerein or its analogs
KR101948048B1 (ko) 2016-12-08 2019-02-14 한양대학교 에리카산학협력단 톡소포자충 ｇｒａ７ 항원 유래 재조합 단백질을 유효성분으로 포함하는 결핵 예방 또는 치료용 약학 조성물
RU2019123160A (ru) * 2016-12-29 2021-01-29 Юниверсити Оф Майами Способ модуляции активности инфламмасом и воспаления в легком
US11840565B2 (en) * 2016-12-29 2023-12-12 University Of Miami Methods and compositions for treating virus-associated inflammation
US10755739B1 (en) 2016-12-30 2020-08-25 John Fristrom Remote railway crossing programmable device and methods thereof
WO2019060516A1 (en) 2017-09-20 2019-03-28 University Of Miami METHOD FOR DETECTION OF INFLAMMASOME PROTEINS AS BIOMARKERS OF NEUROLOGICAL DISORDERS
SG11202013176VA (en) 2018-07-03 2021-01-28 Univ Miami Compositions and methods for treating inflammasome related diseases or conditions

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170107277A1 (en) 2007-07-30 2017-04-20 University Of Miami Methods of modulating inflammasome activity to treat inflammatory conditions
WO2015016178A1 (ja) 2013-07-29 2015-02-05 国立大学法人鹿児島大学 １，５－ｄ－アンヒドロフルクトースを含むアポトーシス関連スペック様カード蛋白質の機能阻害薬

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Juan Pablo de Rivero Vaccari，Therapeutics Targeting the Inflammasome After Central Nervous System Injury，Transl Res.，2016年，167，35-45
Wu Jiang，Protective Effects of Asiatic Acid Against Spinal Cord Injury-Induced Acute Lung Injury in Rats，Inflammation，2016年，39，1853-61

Also Published As

Publication number Publication date
SG11202013176VA (en) 2021-01-28
CN113316588B (zh) 2025-02-28
PH12020552286A1 (en) 2021-06-21
BR112020026798A2 (pt) 2021-03-30
ZA202100703B (en) 2022-08-31
MX2021000142A (es) 2021-05-12
JP2025067915A (ja) 2025-04-24
AU2019297515A1 (en) 2021-02-25
CA3105129A1 (en) 2020-01-09
CL2020003447A1 (es) 2021-07-30
KR20210071944A (ko) 2021-06-16
ZA202201437B (en) 2024-05-30
JP2021528092A (ja) 2021-10-21
EP3818081A1 (en) 2021-05-12
CO2021001172A2 (es) 2021-07-09
EP3818081A4 (en) 2022-06-22
IL279851A (en) 2021-03-01
WO2020010273A1 (en) 2020-01-09
CN113316588A (zh) 2021-08-27
US12570735B2 (en) 2026-03-10
US20210284723A1 (en) 2021-09-16
JP7850296B2 (ja) 2026-04-22

Similar Documents

Publication Publication Date Title
JP7850296B2 (ja) インフラマソームに関連する疾患又は病態を治療するための組成物及び方法
US10961306B2 (en) Methods for treating lung inflammation with an anti-ASC antibody
US20170015738A1 (en) Antibodies Specific for Hyperphosphorylated Tau and Methods of Use Thereof
US20230238030A1 (en) Methods for modulating inflammasome activity and inflammation in the lung
US11840565B2 (en) Methods and compositions for treating virus-associated inflammation
HK40055003A (zh) 用於治疗炎性小体相关疾病或病症的组合物和方法
US20240124570A1 (en) Inflammasome antibody compositon and method for treating neurologic disorder
JP2025530202A (ja) 神経疾患を治療するためのインフラマソーム抗体組成物及び方法
HK40016017A (en) Method for modulating inflammasome activity and inflammation in the lung
US20230296626A1 (en) Compositions and methods for treating inflammasome related diseases or conditions
EA039569B1 (ru) Антитела, специфичные к гиперфосфорилированному тау-белку, и способы их применения

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220630

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220630

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20230531

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230605

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230904

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20231106

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231205

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240226

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240527

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240726

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20240917

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250116

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250701

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20251001

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251030

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20260123

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20260219

R150 Certificate of patent or registration of utility model

Ref document number: 7824030

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150